The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2022 | The emerging role of ctDNA in cancer diagnostics
Justin Mencel, MBBS, The Royal Marsden NHS Foundation Trust, London, UK, describes where circulating tumor DNA (ctDNA) is heading in the clinical utility of liquid biopsies. This includes using ctDNA to detect minimal residual disease (MRD) to thereby guide adjuvant treatment decisions, in particular in colorectal cancer (CRC), and as a novel diagnostic tool for the detection of cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
